InMed Pharmaceuticals Inc. Compensation Adjustment Letter to Eric Hsu (September 2018)
InMed Pharmaceuticals Inc. has agreed to increase Eric Hsu's base salary to $224,000 and, subject to board approval, grant him 270,000 additional stock options. This adjustment recognizes his increased work commitment to 80% of full time. The options will be issued according to the company's standard policies and priced around the date of the letter. The agreement is effective as of September 1, 2018.
Exhibit 10.4.2
 | InMed Pharmaceuticals, Inc.
|
01 SEPTEMBER 2018
Dear Eric Hsu,
In recognition of your agreement to increase your work commitment to InMed to 80% of full time, I am pleased to make the following changes to your compensation:
Base Salary - will increase to $224,000 as of the date of this letter; and
Options - subject to approval by the Board of Directors, you will be issued an additional 270,000 options to purchase common shares in the Company as per the Company’s standard options policies, priced on or around the date of this letter.
On behalf of the entire Management Team and Board of Directors, thank you for your contributions to the Company’s success and we look forward to achieving more, together.
/s/ Eric A. Adams
Eric A. Adams President and CEO
InMed Pharmaceuticals Inc.
